<DOC>
	<DOCNO>NCT01769417</DOCNO>
	<brief_summary>This Phase 1 , first time human study enrol approximately 33 healthy adult subject ( 18-65 yr ) one study site . The purpose study evaluate safety , tolerability PK MEDI4893 healthy adult volunteer administer single IV dose compare placebo , across 4 cohort . The 4 dose cohort enroll sequentially . Subjects follow safety time Informed Consent 360 day post dose .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Safety , Tolerability , Pharmacokinetics MEDI4893 Healthy Adult Subjects</brief_title>
	<detailed_description>This phase 1 , randomize , double-blind , placebo-controlled , dose-escalation study evaluate safety , tolerability pharmacokinetics MEDI4893 , extend half-life human monoclonal antibody Staphylococcus aureus alpha toxin , healthy adult subject . Approximately 33 subject enrol across 4 fix dose cohort 1 study site . This study last approximately 389 day , constitute screen period 28 day , 1 day investigational product administration , 360 day safety follow period .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age 18 65 year screen . 2 . Written inform consent locally require authorization ( eg , HIPAA ) obtain subject prior performing protocolrelated procedure , include screen evaluation . 3 . Females childbearing age use contraception least 28 day prior receive dose investigational product , 1 year receive IP . 4 . Weight ≥ 45 kg ≤ 110 kg screening . 5 . Healthy medical history physical examination screening . 6 . Systolic blood pressure ( BP ) &lt; 140 mm Hg diastolic BP &lt; 90 mm Hg screening . 7 . Normal electrocardiogram ( ECG ) screening . 8 . Able complete 360day postdose followup period require protocol . 1 . Any condition , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result . 2 . Employees sponsor , clinical study site , individual involve conduct study , immediate family member individual . 3 . Acute illness study entry . 4 . Fever 99.5F high day dose . 5 . Any drug therapy within 7 day prior Day 1 . 6 . Blood donation excess 400 mL within 6 month prior study entry . 7 . Receipt immunoglobulin blood product within 6 month prior study entry . 8 . Receipt prior investigational drug investigational vaccine within 120 day prior investigational product dosing plan dose 9 . Receipt standard vaccine within 14 day prior investigational product dosing . 10 . Previous receipt monoclonal antibody . 11 . Receipt immunosuppressive medication prior year active prior history immunodeficiency . Any course systemic corticosteroid 7 day duration prior year excludes subject . 12 . History allergic disease reaction likely exacerbate component investigational product . 13 . Previous medical history evidence intercurrent illness may compromise safety subject study . 14 . Evidence systemic disease physical examination screening . 15 . Evidence infection ( ie , positive laboratory test result ) hepatitis A , B , C virus human immunodeficiency virus ( HIV ) screening . 16 . Any following screening : 1 . Hemoglobin &lt; 12.0 g/dL male &lt; 11.5 g/dL female . 2 . WBC count &lt; 3,800/mm3 . 3 . Platelet count &lt; 140,000/mm3 . 4 . AST , ALT , BUN , serum creatinine &gt; upper limit normal ( ULN ) . 5 . Positive Urine Class A drug screen . 6 . Other abnormal laboratory value screen panel , opinion principal investigator , judge clinically significant potentially confound study result . 17 . Pregnant nursing mother . 18 . Active alcohol drug abuse history alcohol drug abuse , opinion principal investigator , might compromise subject safety , study safety assessment , ability subject comply study requirement . 19 . Concurrent enrollment another interventional study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>